Concepedia

Author

Matthew McKinney

Duke Medical CenterORCID

Also Known As

M McKinney, Matthew E. McKinney, Matthew McKinney

18

Publications

1.1K

Citations

9

H-Index

17

Concepts

All Affiliations

Duke Medical CenterDuke UniversityCleveland ClinicUniversity of UtahDuke Cancer Institute
MM

About

Matthew McKinney is an author at Duke Medical Center specializing in medicine, pathology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

637

2

Pathology

2

2

626

3

Cell Biology

1

1

11

4

Immunology

1

1

11

5

Pharmacology

1

1

31

Matthew McKinney

×

8

Publications

1.1K

Citations

8

H-Index

YearCitations

The genetic landscape of mutations in Burkitt lymphoma

Cassandra Love, Zhen Sun, Dereje D. Jima,

Nature Genetics

2012

595

The Genetic Basis of Hepatosplenic T-cell Lymphoma

Matthew McKinney, Andrea B. Moffitt, Philippe Gaulard,

Cancer Discovery

2017

195

Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2

Andrea B. Moffitt, Sarah L. Ondrejka, Matthew McKinney,

The Journal of Experimental Medicine

2017

170

GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo

Jane Healy, Adrienne Nugent, Rachel E. Rempel,

Blood

2016

63

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

William G. Wierda, Nirav N. Shah, Chan Y. Cheah,

The Lancet Haematology

2024

31

Induction of Wilms' Tumor Protein (WT1)–Specific Antitumor Immunity Using a Truncated WT1-Expressing Adenovirus Vaccine

Takuya Osada, Christopher Y. Woo, Matthew McKinney,

Clinical Cancer Research

2009

15

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Brian T. Hill, Caroline J Roth, Rachel Kositsky,

Blood

2021

13

Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function

Michael A. Morse, Amy Hobeika, Delila Serra,

Cancer Gene Therapy

2011

11

Page 1